ATE369130T1 - Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen - Google Patents

Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen

Info

Publication number
ATE369130T1
ATE369130T1 AT02714978T AT02714978T ATE369130T1 AT E369130 T1 ATE369130 T1 AT E369130T1 AT 02714978 T AT02714978 T AT 02714978T AT 02714978 T AT02714978 T AT 02714978T AT E369130 T1 ATE369130 T1 AT E369130T1
Authority
AT
Austria
Prior art keywords
carbamat
prevention
compounds
treatment
motion disorders
Prior art date
Application number
AT02714978T
Other languages
English (en)
Inventor
Carlos R Plata-Salaman
Boyu Zhao
Roy E Twyman
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE369130T1 publication Critical patent/ATE369130T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02714978T 2001-02-27 2002-02-21 Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen ATE369130T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27168301P 2001-02-27 2001-02-27
US10/081,501 US6589985B2 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating movement disorders

Publications (1)

Publication Number Publication Date
ATE369130T1 true ATE369130T1 (de) 2007-08-15

Family

ID=26765643

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02714978T ATE369130T1 (de) 2001-02-27 2002-02-21 Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen

Country Status (27)

Country Link
US (1) US6589985B2 (de)
EP (1) EP1411917B1 (de)
JP (1) JP2004527492A (de)
KR (1) KR100858232B1 (de)
CN (1) CN1262272C (de)
AR (1) AR033426A1 (de)
AT (1) ATE369130T1 (de)
AU (1) AU2002247204B2 (de)
BR (1) BR0207831A (de)
CA (1) CA2439478C (de)
CY (1) CY1106924T1 (de)
CZ (1) CZ20032299A3 (de)
DE (1) DE60221670T2 (de)
DK (1) DK1411917T3 (de)
ES (1) ES2291454T3 (de)
HU (1) HUP0303344A3 (de)
IL (2) IL157592A0 (de)
MX (1) MXPA03007719A (de)
MY (1) MY157373A (de)
NO (1) NO20033803L (de)
NZ (1) NZ551954A (de)
PL (1) PL364679A1 (de)
PT (1) PT1411917E (de)
RS (1) RS50676B (de)
RU (1) RU2294739C2 (de)
TW (1) TWI331524B (de)
WO (1) WO2002067926A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2003445A3 (cs) * 2000-07-21 2004-08-18 Ortho@Mcneilápharmaceuticalźáinc Karbamátové sloučeniny pro prevenci nebo léčbu neuropatické bolesti a bolesti asociované s histaminovou a migrenózní bolestí hlavy
PT1383489E (pt) * 2001-02-27 2007-06-21 Ortho Mcneil Pharm Inc Compostos carbamato para utilização na prevenção ou tratamento de distúrbios neurodegenerativos
PT1408954E (pt) 2001-07-16 2009-07-28 Ortho Mcneil Janssen Pharm Compostos carbamatos para utilização na prevenção ou tratamento da dor neuropática
ES2435403T3 (es) 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
PE20070325A1 (es) * 2005-06-29 2007-05-12 Alza Corp Formas de dosificacion oral que comprenden compuestos derivados de carbamato
CA2616721C (en) * 2005-07-26 2014-01-21 Janssen Pharmaceutica N.V. Methods for treating substance-related disorders
WO2008054984A1 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica, N.V. Treatment of pervasive developmental disorders
KR101783633B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 섬유근육통 증후군의 치료 방법
EP2496228B1 (de) 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Verfahren zur behandlung von aufmerksamkeitsdefizitstörung mit hyperaktivität
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
ES2998534T3 (en) * 2013-03-12 2025-02-20 Bio Pharm Solutions Co Ltd Phenyl carbamate compounds for use in preventing or treating pediatric epilesy
US9907776B2 (en) 2013-03-12 2018-03-06 Bio-Pharm Solutions, Co., Ltd. Phenyl carbamate compound and a composition for preventing or treating a psychiatric disorder comprising the same
JP6807941B2 (ja) * 2016-02-29 2021-01-06 バイオ−ファーム ソリューションズ カンパニー リミテッド スルファメート誘導体化合物、その製造方法および用途
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
JP7086076B2 (ja) * 2016-12-14 2022-06-17 エスケー バイオファーマスティカルズ カンパニー リミテッド 振戦又は振戦症候群の予防、軽減又は治療のためのカルバメート化合物の使用
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
JP2023539291A (ja) * 2020-08-31 2023-09-13 バイオ－ファーム ソリューションズ カンパニー リミテッド 神経変性疾患の予防又は治療用フェニルアルキルカルバメート化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol

Also Published As

Publication number Publication date
CN1505508A (zh) 2004-06-16
DE60221670T2 (de) 2008-04-30
DE60221670D1 (de) 2007-09-20
PL364679A1 (en) 2004-12-13
DK1411917T3 (da) 2007-09-24
CA2439478A1 (en) 2002-09-06
PT1411917E (pt) 2007-09-17
CY1106924T1 (el) 2012-09-26
HK1067305A1 (en) 2005-04-08
CA2439478C (en) 2010-05-18
AR033426A1 (es) 2003-12-17
CN1262272C (zh) 2006-07-05
IL157592A0 (en) 2004-03-28
HUP0303344A2 (hu) 2004-01-28
NO20033803L (no) 2003-10-10
RU2003128985A (ru) 2005-03-10
KR20030074847A (ko) 2003-09-19
IL157592A (en) 2009-12-24
EP1411917A1 (de) 2004-04-28
MY157373A (en) 2016-06-15
EP1411917B1 (de) 2007-08-08
MXPA03007719A (es) 2004-11-12
US20020151585A1 (en) 2002-10-17
AU2002247204B2 (en) 2006-08-24
KR100858232B1 (ko) 2008-09-12
US6589985B2 (en) 2003-07-08
RS50676B (sr) 2010-06-30
WO2002067926A1 (en) 2002-09-06
JP2004527492A (ja) 2004-09-09
HUP0303344A3 (en) 2012-07-30
CZ20032299A3 (cs) 2004-08-18
NO20033803D0 (no) 2003-08-26
TWI331524B (en) 2010-10-11
ES2291454T3 (es) 2008-03-01
RU2294739C2 (ru) 2007-03-10
NZ551954A (en) 2008-07-31
BR0207831A (pt) 2004-06-22
YU67703A (sh) 2006-08-17

Similar Documents

Publication Publication Date Title
ATE369130T1 (de) Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
DE60223694D1 (de) Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE60317061D1 (de) Ibandronsäure zur behandlung und vorbeugung von osteoporose
EP1274444A4 (de) Arzneistoffe zur behandlung psychiatrischer oder abusus-bedingter störungen
DE60239648D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Asthma
DE60224163D1 (de) Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
DE50212701D1 (de) Bestrahlungsanordnung zur behandlung von akne und aknenarben
DE60208186D1 (de) Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrinvermittelten erkrankungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE69925865D1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
DE60233186D1 (de) Verbessertes System zur Behandlung von Elementarschwefel-Rückständen
ATE361745T1 (de) Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE60214355D1 (de) Exemestan zur behandlung von hormonabhängigen störungen
ATE359783T1 (de) Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
ATE346597T1 (de) Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
DE60036723D1 (de) Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1411917

Country of ref document: EP